MAD2L1 and ovarian serous carcinoma: Analysis of the ovarian cohort from the Cancer Genome Atlas Consortium (TCGA, [43] confirmed the overexpression of Mad2 in HGSC versus low-grade serous ovarian carcinoma (LGSC, p = 1.08e−06) and versus normal ovarian tissue (p = 0.001, Figure 5B).